E
BriaCell Therapeutics Corp.
BCT.TO
TSX
E
Sell
1/19/2024Downgrade
BriaCell Therapeutics Corp. (BCT.TO) was downgraded to E+ from D- on 1/19/2024 due to a major decline in the growth index, total return index and solvency index. Earnings per share declined from -$0.1543 to -$0.4966, and EBIT declined 10.35% from -$7.71M to -$8.5M.
BriaCell Therapeutics Corp. (BCT.TO) was downgraded to E+ from D- on 1/19/2024 due to a major decline in the growth index, total return index and solvency index. Earnings per share declined from -$0.1543 to -$0.4966, and EBIT declined 10.35% from -$7.71M to -$8.5M.
D
Sell
3/14/2023Downgrade
BriaCell Therapeutics Corp. (BCT.TO) was downgraded to D- from D on 03/14/2023.
BriaCell Therapeutics Corp. (BCT.TO) was downgraded to D- from D on 03/14/2023.
D
Sell
2/23/2023Upgraded
BriaCell Therapeutics Corp. (BCT.TO) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
BriaCell Therapeutics Corp. (BCT.TO) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
D
Sell
2/8/2023Downgrade
BriaCell Therapeutics Corp. (BCT.TO) was downgraded to D- from D on 2/8/2023 due to a noticeable decline in the total return index, valuation index and solvency index. The quick ratio declined from 43.64 to 38.48.
BriaCell Therapeutics Corp. (BCT.TO) was downgraded to D- from D on 2/8/2023 due to a noticeable decline in the total return index, valuation index and solvency index. The quick ratio declined from 43.64 to 38.48.
D
Sell
5/16/2022Upgraded
BriaCell Therapeutics Corp. (BCT.TO) was upgraded to D from E+ on 05/16/2022.
BriaCell Therapeutics Corp. (BCT.TO) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
BriaCell Therapeutics Corp. (BCT.TO) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
BriaCell Therapeutics Corp. (BCT.TO) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
D
Sell
5/5/2022Upgraded
BriaCell Therapeutics Corp. (BCT.TO) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
BriaCell Therapeutics Corp. (BCT.TO) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
D
Sell
4/20/2022Downgrade
BriaCell Therapeutics Corp. (BCT.TO) was downgraded to D- from D on 4/20/2022 due to a decline in the solvency index, total return index and valuation index. The quick ratio declined from 128.68 to 79.33.
BriaCell Therapeutics Corp. (BCT.TO) was downgraded to D- from D on 4/20/2022 due to a decline in the solvency index, total return index and valuation index. The quick ratio declined from 128.68 to 79.33.
D
Sell
11/15/2021Downgrade
BriaCell Therapeutics Corp. (BCT.V) was downgraded to D from D+ on 11/15/2021 due to a significant decline in the efficiency index, growth index and valuation index. Net income declined 193.32% from $2.88M to -$2.69M, and earnings per share declined from $0.6069 to -$0.2257.
BriaCell Therapeutics Corp. (BCT.V) was downgraded to D from D+ on 11/15/2021 due to a significant decline in the efficiency index, growth index and valuation index. Net income declined 193.32% from $2.88M to -$2.69M, and earnings per share declined from $0.6069 to -$0.2257.
D
Sell
7/21/2021Upgraded
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D+ from D on 7/21/2021 due to a significant increase in the solvency index, efficiency index and volatility index. The quick ratio increased from 0 to 118.28, net income increased 1,377.93% from -$225.2 to $2.88M, and total capital increased 537.8% from -$3.15M to $13.81M.
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D+ from D on 7/21/2021 due to a significant increase in the solvency index, efficiency index and volatility index. The quick ratio increased from 0 to 118.28, net income increased 1,377.93% from -$225.2 to $2.88M, and total capital increased 537.8% from -$3.15M to $13.81M.
D
Sell
12/31/2020Upgraded
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D from D- on 12/31/2020 due to an increase in the growth index and total return index. Operating cash flow increased 78.98% from -$256.9 to -$54, earnings per share increased from -$0.6975 to -$0.4752, and EBIT increased 31.15% from -$513.3 to -$353.4.
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D from D- on 12/31/2020 due to an increase in the growth index and total return index. Operating cash flow increased 78.98% from -$256.9 to -$54, earnings per share increased from -$0.6975 to -$0.4752, and EBIT increased 31.15% from -$513.3 to -$353.4.
D
Sell
12/2/2020Downgrade
BriaCell Therapeutics Corp. (BCT.V) was downgraded to D- from D on 12/2/2020 due to a decline in the growth index, volatility index and total return index. Operating cash flow declined 1,676.07% from $16.3 to -$256.9, and EBIT declined 1.56% from -$505.4 to -$513.3.
BriaCell Therapeutics Corp. (BCT.V) was downgraded to D- from D on 12/2/2020 due to a decline in the growth index, volatility index and total return index. Operating cash flow declined 1,676.07% from $16.3 to -$256.9, and EBIT declined 1.56% from -$505.4 to -$513.3.
D
Sell
7/1/2020Upgraded
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D from D- on 7/1/2020 due to an increase in the growth index and valuation index. Operating cash flow increased 112.66% from -$128.8 to $16.3, EBIT increased 64.59% from -$1.43M to -$505.4, and earnings per share increased from -$1.9814 to -$0.7049.
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D from D- on 7/1/2020 due to an increase in the growth index and valuation index. Operating cash flow increased 112.66% from -$128.8 to $16.3, EBIT increased 64.59% from -$1.43M to -$505.4, and earnings per share increased from -$1.9814 to -$0.7049.
D
Sell
6/4/2020Downgrade
BriaCell Therapeutics Corp. (BCT.V) was downgraded to D- from D on 6/4/2020 due to a decline in the total return index, volatility index and valuation index.
BriaCell Therapeutics Corp. (BCT.V) was downgraded to D- from D on 6/4/2020 due to a decline in the total return index, volatility index and valuation index.
D
Sell
5/20/2020Upgraded
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D from D- on 5/20/2020 due to an increase in the growth index and valuation index.
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D from D- on 5/20/2020 due to an increase in the growth index and valuation index.
D
Sell
4/3/2020Downgrade
BriaCell Therapeutics Corp. (BCT.V) was downgraded to D- from D+ on 4/3/2020 due to a significant decline in the efficiency index, growth index and solvency index. Total capital declined 158.26% from -$816.8 to -$2.11M, the quick ratio declined from 0.05 to 0.03, and EBIT declined 22.2% from -$1.17M to -$1.43M.
BriaCell Therapeutics Corp. (BCT.V) was downgraded to D- from D+ on 4/3/2020 due to a significant decline in the efficiency index, growth index and solvency index. Total capital declined 158.26% from -$816.8 to -$2.11M, the quick ratio declined from 0.05 to 0.03, and EBIT declined 22.2% from -$1.17M to -$1.43M.
D
Sell
2/24/2020Upgraded
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D+ from D on 2/24/2020 due to an increase in the total return index, volatility index and growth index.
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D+ from D on 2/24/2020 due to an increase in the total return index, volatility index and growth index.
D
Sell
1/17/2020Downgrade
BriaCell Therapeutics Corp. (BCT.V) was downgraded to D from D+ on 1/17/2020 due to a decline in the volatility index.
BriaCell Therapeutics Corp. (BCT.V) was downgraded to D from D+ on 1/17/2020 due to a decline in the volatility index.
D
Sell
1/2/2020Upgraded
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D+ from D on 1/2/2020 due to an increase in the volatility index and growth index. EBIT increased 9.23% from -$1.29M to -$1.17M, and earnings per share increased from -$1.9467 to -$1.8245.
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D+ from D on 1/2/2020 due to an increase in the volatility index and growth index. EBIT increased 9.23% from -$1.29M to -$1.17M, and earnings per share increased from -$1.9467 to -$1.8245.
D
Sell
10/23/2019Upgraded
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D from E+ on 10/23/2019 due to a significant increase in the efficiency index, valuation index and total return index.
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D from E+ on 10/23/2019 due to a significant increase in the efficiency index, valuation index and total return index.
E
Sell
10/8/2019Downgrade
BriaCell Therapeutics Corp. (BCT.V) was downgraded to E+ from D- on 10/8/2019 due to a noticeable decline in the efficiency index, valuation index and total return index.
BriaCell Therapeutics Corp. (BCT.V) was downgraded to E+ from D- on 10/8/2019 due to a noticeable decline in the efficiency index, valuation index and total return index.
D
Sell
4/1/2019Upgraded
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D- from E+ on 4/1/2019 due to a noticeable increase in the efficiency index, valuation index and total return index.
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D- from E+ on 4/1/2019 due to a noticeable increase in the efficiency index, valuation index and total return index.
E
Sell
2/25/2019Downgrade
BriaCell Therapeutics Corp. (BCT.V) was downgraded to E+ from D- on 2/25/2019 due to a decline in the total return index, volatility index and valuation index.
BriaCell Therapeutics Corp. (BCT.V) was downgraded to E+ from D- on 2/25/2019 due to a decline in the total return index, volatility index and valuation index.
D
Sell
12/28/2018Upgraded
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D- from E+ on 12/28/2018 due to a noticeable increase in the growth index and efficiency index. Earnings per share increased from -$0.0104 to -$0.005, net income increased 51.1% from -$1.64M to -$804.1, and EBIT increased 33.04% from -$1.47M to -$987.1.
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D- from E+ on 12/28/2018 due to a noticeable increase in the growth index and efficiency index. Earnings per share increased from -$0.0104 to -$0.005, net income increased 51.1% from -$1.64M to -$804.1, and EBIT increased 33.04% from -$1.47M to -$987.1.
E
Sell
10/4/2018Downgrade
BriaCell Therapeutics Corp. (BCT.V) was downgraded to E+ from D- on 10/4/2018 due to a decline in the solvency index, efficiency index and valuation index. Debt to equity increased from 0.42 to 1.18, the quick ratio declined from 2.5 to 1.32, and total capital declined 38.01% from $3.33M to $2.07M.
BriaCell Therapeutics Corp. (BCT.V) was downgraded to E+ from D- on 10/4/2018 due to a decline in the solvency index, efficiency index and valuation index. Debt to equity increased from 0.42 to 1.18, the quick ratio declined from 2.5 to 1.32, and total capital declined 38.01% from $3.33M to $2.07M.
D
Sell
8/3/2018Upgraded
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D- from E+ on 8/3/2018 due to an increase in the volatility index and total return index.
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D- from E+ on 8/3/2018 due to an increase in the volatility index and total return index.
E
Sell
7/19/2018Downgrade
BriaCell Therapeutics Corp. (BCT.V) was downgraded to E+ from D- on 7/19/2018 due to a decline in the total return index and volatility index.
BriaCell Therapeutics Corp. (BCT.V) was downgraded to E+ from D- on 7/19/2018 due to a decline in the total return index and volatility index.
D
Sell
7/2/2018Upgraded
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D- from E+ on 7/2/2018 due to an increase in the total return index, volatility index and valuation index.
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D- from E+ on 7/2/2018 due to an increase in the total return index, volatility index and valuation index.
E
Sell
3/5/2018Downgrade
BriaCell Therapeutics Corp. (BCT.V) was downgraded to E+ from D- on 3/5/2018 due to a decline in the total return index and volatility index.
BriaCell Therapeutics Corp. (BCT.V) was downgraded to E+ from D- on 3/5/2018 due to a decline in the total return index and volatility index.
D
Sell
12/29/2017Upgraded
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D- from E+ on 12/29/2017 due to an increase in the efficiency index, solvency index and volatility index. The quick ratio increased from 1.83 to 3.07, net income increased 43.03% from -$899.9 to -$512.7, and total capital increased 31.3% from $747.9 to $982.
BriaCell Therapeutics Corp. (BCT.V) was upgraded to D- from E+ on 12/29/2017 due to an increase in the efficiency index, solvency index and volatility index. The quick ratio increased from 1.83 to 3.07, net income increased 43.03% from -$899.9 to -$512.7, and total capital increased 31.3% from $747.9 to $982.
E
Sell
11/24/2017Downgrade
BriaCell Therapeutics Corp. (BCT.V) was downgraded to E+ from D- on 11/24/2017 due to a decline in the solvency index, efficiency index and total return index. The quick ratio declined from 114.02 to 1.83, total capital declined 52.47% from $1.57M to $747.9, and net income declined 1.65% from -$885.3 to -$899.9.
BriaCell Therapeutics Corp. (BCT.V) was downgraded to E+ from D- on 11/24/2017 due to a decline in the solvency index, efficiency index and total return index. The quick ratio declined from 114.02 to 1.83, total capital declined 52.47% from $1.57M to $747.9, and net income declined 1.65% from -$885.3 to -$899.9.
D
Sell
10/20/2017Downgrade
BriaCell Therapeutics Corp. (BCT.V) was downgraded to D- from D+ on 10/20/2017 due to a significant decline in the volatility index, total return index and efficiency index. Net income declined 184.66% from -$311 to -$885.3.
BriaCell Therapeutics Corp. (BCT.V) was downgraded to D- from D+ on 10/20/2017 due to a significant decline in the volatility index, total return index and efficiency index. Net income declined 184.66% from -$311 to -$885.3.
D
Sell
7/7/2014Downgrade
Ansell Capital Corp. (ACP.V) was downgraded to D+ from C- on 7/7/2014 due to a major decline in the growth index, volatility index and total return index.
Ansell Capital Corp. (ACP.V) was downgraded to D+ from C- on 7/7/2014 due to a major decline in the growth index, volatility index and total return index.
C
Hold
4/30/2014Upgraded
Ansell Capital Corp. (ACP.V) was upgraded to C- from D+ on 4/30/2014 due to a substantial increase in the volatility index, total return index and growth index. EBIT increased 4.75% from -$80 to -$83.8.
Ansell Capital Corp. (ACP.V) was upgraded to C- from D+ on 4/30/2014 due to a substantial increase in the volatility index, total return index and growth index. EBIT increased 4.75% from -$80 to -$83.8.
